Anti-infectives:

• A Novel Surfactant Nanoemulsion with Broad-spectrum Sporicidal Activity against Bacillus Species. Hamouda T, Hayes M, Cao Z, Tonda R, Johnson K, Wright DC, Brisker J, Baker JR Jr (1999). The Journal of Infectious Diseases 180:1939-49.

• Antimicrobial Mechanism of Action of Surfactant Lipid Preparations in Enteric Gram-negative Bacilli.  Hamouda T, Baker JR Jr (2000) Journal of Applied Microbiology 89:397-403.  Download PDF (2100K) 

• A Novel Surfactant Nanoemulsion with a Unique Non-irritant Topical Antimicrobial Activity against Bacteria, enveloped Viruses and Fungi. Hamouda T, Myc A, Donovan B, Shih A, Reuter J, Baker J, Jr (2001). Microbiological Research 156: 1-7.

• The Fungicidal Activity of Novel Nanoemulsion (X8W60PC) against Clinically Important Yeast and Filamentous Fungi. Myc A, Vanhecke T, Landers JJ, Hamouda T, Baker Jr. JR (2001). Mycopathologia 155: 195-201, (2002).

• In Vitro Activities of a Novel Nanoemulsion against Burkholderia and
  Other Multidrug-Resistant Cystic Fibrosis-Associated Bacterial Species.
  LiPuma J, Rathinavelu S, Foster B, Keoleian J, Makidon P, Kalikin L, Baker J, Jr., Antimicrobial Agents & Chemotherapy, Jan. 2009, p. 249–255.

• NB-002, a Novel Nanoemulsion with Broad Antifungal Activity against
  Dermatophytes, Other Filamentous Fungi, and Candida albicans. J. Pannu, McCarthy, A. Martin, T. Hamouda, S. Ciotti, A. Fothergill, and J. Sutcliffe, Antimicrobial Agents & Chemotherapy, Aug. 2009, p. 3273–3279 Vol. 53, No. 8

• Topical Nanoemulsion Therapy Reduces Bacterial Wound Infection and
  Inflammation after Burn Injury. Mark R. Hemmila, Aladdein Mattar, Michael A. Taddonio, Saman Arbabi, Tarek Hamouda, Peter A. Ward, Stewart C. Wang, James R. Baker Jr, Surgery, 2010.01.001

• In Vitro Antibacterial Activity of NB-003 against Propionibacterium acnes.
  J Pannu, A. McCarthy, A. Martin, T. Hamouda, S. Ciotti, L. Ma, J. Sutcliffe, and J. R. Baker, Jr., Antimicrobial Agents and Chemotherapy, Sep 2011; 55: 4211 - 4217
  

Vaccines/Adjuvants:

• Prevention of Murine Influenza A Virus Pneumonitis by Surfactant Nanoemulsions. Donovan BW, Reuter JD, Cao Z, Myc A, Johnson KJ, and Baker Jr. Antiviral Chemistry & Chemotherapy; 11: 41-49, (2000). 

• Development of Immune Response that Protects Mice from Viral Pneumonitis after a Single Intranasal Immunization with Influenza A Virus and Nanoemulsion. Myc A, Kukowska-Latallo JF, Bielinska AU, Cao P, Myc PP, Janczak K, Sturm TR, Grabinski MS, Landers JJ, Young K, Chang J, Hamouda T, Olszewski MA, Baker, Jr JR. Vaccine; 21: 3801-3814, (2003).

• Mucosal Immunization with a Novel Nanoemulsion-Based Recombinant Anthrax Protective Antigen Vaccine Protects against Bacillus anthracis Spore Challenge. Anna U. Bielinska, Katarzyna W. Janczak, Jeffrey J. Landers, Paul Makidon, Laurie E. Sower, Johnny W. Peterson, and James R. Baker, Jr.; Infection and Immunity, p. 4020–4029 Vol. 75, No. 8, (2007).

• Pre-Clinical Evaluation of a Novel Nanoemulsion-Based Hepatitis B Mucosal Vaccine. Paul E. Makidon, Anna U. Bielinska, Shraddha S. Nigavekar, Katarzyna W. Janczak, Jessica Knowlton, Alison J. Scott, Nicholas Mank, Zhengyi Cao, Sivaprakash Rathinavelu, Michael R. Beer, J. Erby Wilkinson, Luz P. Blanco, Jeffrey J. Landers, James R. Baker, Jr.; Plos ONE, 8/2008, Volume 3, Issue 8.

• Nasal Immunization with a Recombinant HIV gp120 and Nanoemulsion Adjuvant Produces TH1 Polarized Responses and Neutralizing Antibodies to Primary HIV Type 1 Isolates.  Ann U Bielinska, Katarzyna W. Janczak, Jeffrey J. Landers, David C. Montefiori, and James R. Baker, Jr. AIDS Research and Human Retroviruses, Volume 24, Number 2, 2008

• A Novel, Killed-Virus Nasal Vaccinia Virus Vaccine.  Ann U Bielinska, Alexander A. chepurnov, Jeffrey J. Landers, Katarzyna W. Janczak, Tatiana S. Chepurnova, Gary D. Luker, and James R. Baker, Jr. Clinical and Vaccine Immunology, Feb 2008, p.348-358.

• Efficacy, Immunogenicity and Stability of a Novel Intranasal Nanoemulsion-Adjuvanted Influenza. Tarek Hamouda, Alexander Chepurnov, Nicholas Mank, Jessica Knowlton, Tatiana Chepurnova, Andrzej Myc, Joyce Sutcliffe and James R. Baker, Jr; Human Vaccines 6:7, 1-10; July 2010

• Intranasal Immunization of Ferrets with Commercial Trivalent Influenza Vaccines Formulated in a Nanoemulsion-Based Adjuvant. Tarek Hamouda, Joyce A. Sutcliffe, Susan Ciotti and James R. Baker, Jr. Clinical and Vaccine Immunology, July 2011,p. 1167-1175, Vol. 18, No. 7

  http://cvi.asm.org/cgi/content/full/18/7/1167

• A Novel Inactivated Intranasal Respiratory Syncytial Virus Vaccine Promotes Viral Clearance without Th2 Associated Vaccine-Enhanced Disease. Dennis M. Lindell, Susan B. Morris, Maria P. White1, Lara E. Kallal, Phillip K. Lundy, Tarek Hamouda, James R. Baker Jr, Nicholas W. Lukacs; Plos ONE,

  July 2011, Volume 6, Issue 7, e21823

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0021823

• Safety and Immunogenicity of a Novel Nanoemulsion Mucosal Adjuvant W805EC Combined with Approved Seasonal Influenza Antigens. L.R. Stanberry, J.K. Simon, C. Johnson, P.L. Robinson, J. Morry, M.R. Flack, S. Gracon, A. Myc, T. Hamoudab, J.R. Baker Jr; Vaccine, Volume 30, Issue 2, 5 January 2012, Pages 307–316